Previous Close | 0.2280 |
Open | 0.2195 |
Bid | 0.2265 x 30000 |
Ask | 0.2360 x 30000 |
Day's Range | 0.2195 - 0.2195 |
52 Week Range | 0.1994 - 3.1500 |
Volume | |
Avg. Volume | 20 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Mithra reports full year 2023 financial results Revenues were EUR 40.2 million, down from the 2022 result of EUR 67.0 million which was positively impacted by exceptional upfront cash payments from partnerships.Product sales were EUR 18.7 million, up +19.3% vs EUR 15.7 million in 2022.ESTELLE® product sales reached EUR 10.4 million in 2023 beating the September 2023 guidance of EUR 8.5 million and up from EUR 9.2 million in 2022.Cash position, at EUR 9.0 million at end of 2023, is down compared
Mithra announces changes to its executive management Liege, Belgium, 05 March 2024 – 07:00 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces the termination of the management agreement with David Horn Solomon1 as CEO and his replacement by Christophe Maréchal2 and Xavier Paoli as co-CEOs. As announced today, Mithra will commence a monetization process involving the sale of various selected assets of Mithra and/or the business as a whole (the "Monetiz
Mithra initiates monetization process, receives bridge loan from existing lenders Mithra appoints advisors and initiates a process to monetize its assets or execute a sale of its businessMithra has entered into a new secured bridge loan facility in a committed amount of up to EUR 13.5 million, subject to milestones; with an uncommitted facility of a further EUR 5 millionBridge loan facility provides expected liquidity runway to fund the monetization process with respect to key assets through 30